Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Inspire IVF PCLBKK:IVF -1.30%18 Debt-to-EBITDA is -2.85 as of Jun. 2026. GuruFocus rates BKK:IVF with a GF Score™ of 18/100. The stock has 3 warning signs investors should review. Among 482 Healthcare Providers & Services companies, Inspire IVF PCL ranks worse than 207468.67% on this metric.
Debt-to-EBITDA measures a company's ability to pay off its debt.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for Inspire IVF PCL's Debt-to-EBITDA or its related term are showing as below:
BKK:IVF'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: -16.71 Med: 1.01 Max: 5.66
Current: -4.33
During the past 5 years, the highest Debt-to-EBITDA Ratio of Inspire IVF PCL was 5.66. The lowest was -16.71. And the median was 1.01.
BKK:IVF's Debt-to-EBITDA is ranked worse than 100% of 482
companies
in the Healthcare Providers & Services industry
Industry Median: 2.185
vs BKK:IVF: -4.33
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Inspire IVF PCL Debt-to-EBITDA Related Terms
Inspire IVF PCL Debt-to-EBITDA Historical Data
* Premium members only.
The historical data trend for Inspire IVF PCL's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BKK:IVF vs HCA, THC, DVA: Debt-to-EBITDA Comparison
For the Medical Care Facilities subindustry, Inspire IVF PCL's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Inspire IVF PCL Debt-to-EBITDA vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Inspire IVF PCL's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Inspire IVF PCL's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is four times the quarterly (Jun. 2026) EBITDA data.
Inspire IVF PCL (BKK:IVF) has a Debt-to-EBITDA of -2.85 as of Jun. 2026. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Inspire IVF PCL. According to the industry distribution chart, Inspire IVF PCL ranks #999999 out of 482 companies in the Healthcare Providers & Services industry.
Is Inspire IVF PCL's Debt-to-EBITDA too high?
Inspire IVF PCL's current Debt-to-EBITDA is -2.85. Based on the distribution chart, Inspire IVF PCL ranks #999999 out of 482 companies in the Healthcare Providers & Services industry, which is in the bottom quartile relative to peers. Overall, Inspire IVF PCL has a GF Score™ of 18/100, reflecting its overall financial health beyond just this single metric.
How does Inspire IVF PCL's Debt-to-EBITDA compare to HCA and THC?
According to the Healthcare Providers & Services industry distribution chart, Inspire IVF PCL ranks #999999 out of 482 companies for Debt-to-EBITDA. This places Inspire IVF PCL in the lower half of its industry. The industry median Debt-to-EBITDA is 2.19. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Healthcare Providers & Services company?
The median Debt-to-EBITDA among Healthcare Providers & Services companies is 2.19, based on 482 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Inspire IVF PCL. For the Healthcare Providers & Services industry, the median Debt-to-EBITDA is 2.19 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Inspire IVF PCL's current Debt-to-EBITDA is -2.85. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Inspire IVF PCL stock overvalued right now?
Inspire IVF PCL (BKK:IVF) has a current Debt-to-EBITDA of -2.85. The current Debt-to-EBITDA is -2.85. Inspire IVF PCL's overall GF Score™ is 18/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Inspire IVF PCL (BKK:IVF), the current Debt-to-EBITDA is -2.85 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Inspire IVF PCL operates a comprehensive fertility treatment center, offering services ranging from consultations to selecting the appropriate treatment for each couple. It is principally engaged in infertility treatment and counseling services treatment with anti-aging medicine and health restoration, hemodialysis, blood filtration, and plasma filtration. The company operates in a single geographic area, Thailand.
18GF Score
Get the complete analysis for BKK:IVF
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BKK:IVF has been successfully added to your 
